{"disease":{"id":"allergic-conjunctivitis","name":"Allergic conjunctivitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":76,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"prednisone","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"epinastine","indication_name":"Prevention of itching due to allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elestat","generic_name":"EPINASTINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Adrenergic Receptor Agonist","quality_score":10,"revenue":null,"mechanism":"Elestat works by binding to the histamine H1 receptor, blocking the action of histamine and reducing allergic symptoms."},{"drug_id":"bepotastine-besilate-ophthalmic-solution","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"bepotastine besilate ophthalmic solution","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"H1-receptor, mast cells","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Bepotastine blocks H1 receptors and inhibits histamine release from mast cells."},{"drug_id":"alimemazine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temaril","generic_name":"alimemazine","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"trimeprazine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"doxylamin","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxylamin","company_name":"St. Petersburg Bekhterev Research Psychoneurological Institute","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dexbrompheniramine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drixoral","generic_name":"DEXBROMPHENIRAMINE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexbrompheniramine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"diphenylpyraline","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hispril","generic_name":"DIPHENYLPYRALINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"diphenylpyraline","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"tripelennamine-citrate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyribenzamin","generic_name":"TRIPELENNAMINE CITRATE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"tripelennamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mepyramine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrilamine","generic_name":"mepyramine","company_name":"Impax Labs","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"acrivastine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Semprex-D","generic_name":"ACRIVASTINE","company_name":"Auxilium Pharms Inc","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"phenylpropanolamine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Propadrine","generic_name":"PHENYLPROPANOLAMINE","company_name":"Alpharma Us Pharms","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Indirectly Acting Sympathomimetic Amines","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"antazoline","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenazoline","generic_name":"ANTAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"antazoline","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"loteprednol-etabonate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotemax","generic_name":"LOTEPREDNOL ETABONATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tobramycin","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"fluorometholone","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fml","generic_name":"FLUOROMETHOLONE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chlorpheniramine-maleate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"CHLORPHENIRAMINE MALEATE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"emedastine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emadine","generic_name":"EMEDASTINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Inhibitor","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxyzine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxyzine Hydrochloride","generic_name":"HYDROXYZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"medrysone","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrifar","generic_name":"MEDRYSONE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"tazanolast","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazanol","generic_name":"TAZANOLAST","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"tazanolast","quality_score":19,"revenue":null,"mechanism":"Tazanolast works by inhibiting the action of a specific enzyme involved in the allergic response."},{"drug_id":"fexofenadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allegra","generic_name":"fexofenadine","company_name":"Generic (originally Hoechst Marion Roussel/Sanofi)","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor","drug_class":"Second-generation antihistamine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ketotifen","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zaditor","generic_name":"KETOTIFEN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Inhibitor","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"cyproheptadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyproheptadine Hydrochloride","generic_name":"CYPROHEPTADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"cyproheptadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nedocromil","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alocril","generic_name":"NEDOCROMIL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"doxylamine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unisom","generic_name":"DOXYLAMINE","company_name":"Chattem","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"trometamol","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tham","generic_name":"trometamol","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"trometamol","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"cromoglicic-acid","indication_name":"Allergic Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intal","generic_name":"cromoglicic acid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"cromoglicic-acid","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intal","generic_name":"cromoglicic acid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"lotemax","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lotemax","company_name":"Tufts Medical Center","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"cyclizine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Marezine","generic_name":"CYCLIZINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"cyclizine","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"terfenadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seldane","generic_name":"TERFENADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"High Risk QT Prolonging Agents","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"acitazanolast","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepelin","generic_name":"ACITAZANOLAST","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"acitazanolast","quality_score":null,"revenue":null,"mechanism":"Acitazanolast works by blocking the action of mast cells, which are involved in the allergic response."},{"drug_id":"phenylephrine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"quifenadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phencarol","generic_name":"QUIFENADINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"quifenadine","quality_score":null,"revenue":null,"mechanism":"Phencarol works by blocking the action of histamine, a chemical released by the body during an allergic reaction."},{"drug_id":"astemizole","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hismanal","generic_name":"ASTEMIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"chlorcyclizine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Perazyl","generic_name":"CHLORCYCLIZINE","company_name":"","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"chlorcyclizine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"benadryl","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Benadryl","company_name":"Brooke Army Medical Center","drug_phase":"discontinued","molecular_target":"Histamine H4 receptor, Solute carrier family 22 member 2, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"cromoglicate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglicate","company_name":"LEO Pharma","drug_phase":"discontinued","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cromoglicate","indication_name":"Allergic Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglicate","company_name":"LEO Pharma","drug_phase":"discontinued","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"diphenhydramine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benadryl","generic_name":"diphenhydramine","company_name":"Johnson & Johnson (McNeil Consumer Healthcare)","drug_phase":"marketed","molecular_target":"Histamine H4 receptor, Solute carrier family 22 member 2, 5-hydroxytryptamine receptor 2A","drug_class":"First-generation antihistamine, Sedative","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cetirizine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyrtec","generic_name":"cetirizine","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pecazine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pecazine","company_name":"","drug_phase":"unknown","molecular_target":"5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ephedrine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akovaz","generic_name":"EPHEDRINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"Norepinephrine Releasing Agent","quality_score":52,"revenue":null,"mechanism":"Akovaz works by releasing norepinephrine, a natural chemical in the body that helps to relieve symptoms of respiratory and allergic conditions."},{"drug_id":"hydrocortisone","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tramazoline","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhinol","generic_name":"TRAMAZOLINE","company_name":"","drug_phase":"phase_2","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"tramazoline","quality_score":null,"revenue":null,"mechanism":"Rhinol works by activating the alpha-2A adrenergic receptor to constrict blood vessels in the nasal passages."},{"drug_id":"bepotastine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bepreve","generic_name":"BEPOTASTINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"H1-receptor, mast cells","drug_class":"Histamine-1 Receptor Antagonist","quality_score":48,"revenue":null,"mechanism":"Bepotastine blocks H1 receptors and inhibits histamine release from mast cells."},{"drug_id":"patanol","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Patanol","company_name":"ORA, Inc.","drug_phase":"marketed","molecular_target":"Histamine H1 receptor, Histamine H1 receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"desloratadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clarinex","generic_name":"desloratadine","company_name":"Generic (originally Schering-Plough/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"Histamine-1 Receptor Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties."},{"drug_id":"loratadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claritin","generic_name":"loratadine","company_name":"Generic (originally Schering-Plough)","drug_phase":"marketed","molecular_target":"Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methapyrilene","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thenylene","generic_name":"METHAPYRILENE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"promethazine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan","generic_name":"promethazine","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR","drug_class":"Phenothiazine antihistamine/antiemetic","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"pseudoephedrine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed","generic_name":"pseudoephedrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"Nasal decongestant (sympathomimetic)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"epinastine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elestat","generic_name":"EPINASTINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Adrenergic Receptor Agonist","quality_score":10,"revenue":null,"mechanism":"Elestat works by binding to the histamine H1 receptor, blocking the action of histamine and reducing allergic symptoms."},{"drug_id":"ketorolac","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toradol","generic_name":"KETOROLAC","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"Cyclooxygenase Inhibitor","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"fluorometholone-acetate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flarex","generic_name":"FLUOROMETHOLONE ACETATE","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"alcaftadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lastacaft","generic_name":"ALCAFTADINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":"Lastacaft blocks histamine at the H1 receptor to reduce allergic symptoms."},{"drug_id":"azelastine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Astelin","generic_name":"AZELASTINE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"dexchlorpheniramine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexchlorpheniramine Maleate","generic_name":"DEXCHLORPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexchlorpheniramine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chlorphenamine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"chlorphenamine","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"triprolidine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actidil","generic_name":"TRIPROLIDINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"triprolidine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"brompheniramine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimetane-Dx","generic_name":"BROMPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"brompheniramine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"loteprednol","indication_name":"allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loteprednol Etabonate","generic_name":"LOTEPREDNOL","company_name":"Bausch And Lomb","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"carbinoxamine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Karbinal Er","generic_name":"CARBINOXAMINE","company_name":"Mcneil","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Karbinal Er works by blocking the histamine H1 receptor, a key player in the body's allergic response."},{"drug_id":"azatadine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azatidine","generic_name":"AZATADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"azatadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clemastine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavist","generic_name":"CLEMASTINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"clemastine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cortisol","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxizine","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxizine","company_name":"King Faisal Specialist Hospital & Research Center","drug_phase":"phase_1","molecular_target":"5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"clemastin","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clemastin","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Cytochrome P450 2C19, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenylpropanol","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenylpropanol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bepreve","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bepreve","company_name":"North Texas Institute for Clinical Trials","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"desloratadin","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Desloratadin","company_name":"Max Zeller Soehne AG","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cromoglycate","indication_name":"Allergic Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglycate","company_name":"Vishwajit Nimgaonkar, MD PhD","drug_phase":"phase_3","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cromoglycate","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglycate","company_name":"Vishwajit Nimgaonkar, MD PhD","drug_phase":"phase_3","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pataday","indication_name":"Allergic conjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pataday","company_name":"Merck Sharp & Dohme LLC","drug_phase":"marketed","molecular_target":"Histamine H1 receptor, Histamine H1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":83,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03812952","title":"China Red Eye Study on Allergic Conjunctivitis","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03101618","title":"Animal Allergy in Korean Pet Owners, Pet-related Industry Workers, and Laboratory Animal Reseachers","phase":"","overall_status":"COMPLETED","enrollment_count":643,"lead_sponsor_name":"Gachon University Gil Medical Center","has_results":false},{"nct_id":"NCT01694836","title":"Depigoid Birch 5000 Longterm Study in Adults and Adolescents","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":634,"lead_sponsor_name":"Leti Pharma GmbH","has_results":false},{"nct_id":"NCT05540717","title":"Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":555,"lead_sponsor_name":"Allergy Therapeutics","has_results":true},{"nct_id":"NCT05668390","title":"Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Stallergenes Greer","has_results":false},{"nct_id":"NCT05815758","title":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":512,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT04476433","title":"Intervention in Chronic Pediatric Patients and Their Families.","phase":"NA","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University of Valencia","has_results":false},{"nct_id":"NCT02761252","title":"Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"Menarini International Operations Luxembourg SA","has_results":true},{"nct_id":"NCT05191186","title":"Documentation of Efficacy of Intralymphatic Allergen Immunotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT06063044","title":"Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children","phase":"","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04709575","title":"Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT07309432","title":"Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03494504","title":"ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Aldeyra Therapeutics, Inc.","has_results":true},{"nct_id":"NCT00331500","title":"Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"Alcon Research","has_results":false},{"nct_id":"NCT06212973","title":"A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","has_results":false},{"nct_id":"NCT04541004","title":"Adolescent Mite Allergy Safety Evaluation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"ALK-Abelló A/S","has_results":true},{"nct_id":"NCT05591755","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT03479307","title":"A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Faes Farma, S.A.","has_results":true},{"nct_id":"NCT05430919","title":"Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05579730","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT03850626","title":"Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Leti Pharma GmbH","has_results":false},{"nct_id":"NCT06459219","title":"Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Sven Schneider, MD","has_results":false},{"nct_id":"NCT02844842","title":"Evaluation of Tolerability and Safety of \"Allergovac Poliplus\" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Roxall Medicina España S.A","has_results":false},{"nct_id":"NCT03365648","title":"Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"NTC srl","has_results":false},{"nct_id":"NCT05839938","title":"The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":150,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT01437982","title":"A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":false},{"nct_id":"NCT07427576","title":"Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte","phase":"","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Inmunotek S.L.","has_results":false},{"nct_id":"NCT06800274","title":"Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona","has_results":false},{"nct_id":"NCT05234554","title":"The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Aldeyra Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03821077","title":"Study to Evaluate the Efficacy and Safety of \"Allergovac Poliplus\" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Roxall Medicina España S.A","has_results":false},{"nct_id":"NCT03231969","title":"A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Faes Farma, S.A.","has_results":true},{"nct_id":"NCT03320434","title":"Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"ORA, Inc.","has_results":true},{"nct_id":"NCT04389034","title":"Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Allergy Therapeutics","has_results":false},{"nct_id":"NCT04502966","title":"Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07096440","title":"Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":105,"lead_sponsor_name":"Allergopharma GmbH & Co. KG","has_results":false},{"nct_id":"NCT04984941","title":"Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04776096","title":"Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Laboratorios Poen","has_results":false},{"nct_id":"NCT04050865","title":"A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":true},{"nct_id":"NCT03368339","title":"Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Realm Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04207736","title":"The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Aldeyra Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05641272","title":"Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Inmunotek S.L.","has_results":false},{"nct_id":"NCT03755557","title":"Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Marinomed Biotech AG","has_results":false},{"nct_id":"NCT04176185","title":"A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":80,"lead_sponsor_name":"ALK-Abelló A/S","has_results":false},{"nct_id":"NCT06293820","title":"A Study Of TL-925 For The Treatment of AC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT03820154","title":"Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest","phase":"NA","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Prof. Dr. Claus Bachert BVBA","has_results":false},{"nct_id":"NCT06778213","title":"Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Wroclaw Medical University","has_results":false},{"nct_id":"NCT06686472","title":"Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT03489941","title":"A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT06602726","title":"A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04898686","title":"Probiotic Chewables in Allergic Rhinoconjunctivitis Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false}],"total":50},"guidelines":[{"drug_id":"dexamethasone","guideline_body":"FDA label","recommendation":"Dexamethasone is indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"dexamethasone","guideline_body":"FDA label","recommendation":"Dexamethasone is indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"dexamethasone","guideline_body":"FDA label","recommendation":"Dexamethasone is indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"dexamethasone","guideline_body":"FDA label","recommendation":"Dexamethasone is indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}